Navigation Links
Independent Laboratory Testing Demonstrates Important Quality Differences Between FDA-Approved Makena® and Compounded 17P Formulations
Date:11/8/2011

ncern and Liquidity Considerations" in the Notes to the Consolidated Financial Statements included in Part I, Item 1 of our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2011;
  • risks associated with the introduction and growth strategy related to the Company's Makena® product, including:
    1. the impact of competitive, commercial payor, governmental (including Medicaid program), physician, patient, public or political responses and reactions, and responses and reactions by medical professional associations and advocacy groups, on the Company's sales, marketing, product pricing, product access and strategic efforts;
    2. the possibility that the benefit of any period of exclusivity resulting from the designation of Makena® as an orphan drug may not be realized as a result of U.S. Food and Drug Administration (the "FDA")'s decision to decline to take enforcement action with regards to compounded alternatives;
    3. the Center for Medicare and Medicaid Services' ("CMS") policy regarding Medicaid reimbursement for Makena®, and the resulting coverage decisions for Makena® by various state Medicaid and commercial payors;
    4. the satisfaction or waiver of the terms and conditions for our continued ownership of the full U.S. and worldwide rights to Makena® set forth in the previously disclosed Makena® acquisition agreement, as amended, including a $107.5 million scheduled payment by us for those rights; and
    5. the number of preterm births for which Makena® may be prescribed, its safety and side effects profiles and acceptance of pricing;
  • the possibility of delay or inability to obtain FDA approvals of Clindesse® and Gynazole-1® and the possibility that any product relaunch may be delayed or unsuccessful;
  • risks related to compliance with various agreements and settlements with governmental entities which are discussed in Part I,
    '/>"/>

  • SOURCE Ther-Rx Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Adeona Appoints Jeff Lucero Riley as Independent Chairman
    2. NCPA Digest Finds Independent Community Pharmacies Reducing Health Costs Through Generic Drug Use, Patient Counseling
    3. Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics Pixantrone PIX301 Pivotal Trial
    4. China Medicine Corporation Appoints PricewaterhouseCoopers As Independent Auditor To Audit Results For Fiscal Years 2006 - 2010
    5. New Report: Independent Drugstores Thrive in Economic Recession
    6. NeoStem Appoints Grant Thornton LLP as New Independent Registered Public Accounting Firm
    7. Independent Expert Panel Calls for Information on Fragrance Ingredients Under Review
    8. Nearly 7,000 Participate in Cardinal Healths Largest-Ever Annual Trade Show for Independent Pharmacies
    9. As Economic Recovery Sputters, Independent Drugstores Shouldnt Shoulder Employers With Higher Costs
    10. Independent Drugstore Lobbyists Try to Pad Profits at the Expense of Small Business
    11. Florida Independent Drugstores Attack Mail-Service Pharmacies, Put Profits Ahead of Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2014)... , August 27, 2014 ... Equipment Market By Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental ... published by MarketsandMarkets, the global Dental Equipment Market is ... $5,416.3 million in 2014, growing at a CAGR ... Browse 95 market data tables and 61 figures ...
    (Date:8/27/2014)... , Aug. 27, 2014 Pulse Systems, ... (EHR) , Practice Management , and Revenue Cycle ... known business practices performed by some RCM vendors, at UBM ... PA on September 19-20, 2014.  ... will return in September with a new session encouraging practices ...
    (Date:8/27/2014)... HONG KONG , Aug. 27, 2014 /PRNewswire/ ... ("Sihuan Pharmaceutical" or the "Company"), a leading pharmaceutical ... franchise in China,s prescription ... of the Company and its subsidiaries (collectively the ... 2014 (the "Period"). Financial HighlightsFor the ...
    Breaking Medicine Technology:Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 2Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 4Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7
    ... (Nasdaq: STXS ) announced today financial results for ... with the preliminary results reported on October 13, 2010. Third ... and reductions in both operating loss and net loss. ... compared to $13.3 million in the third quarter 2009. As ...
    ... Quality Forum (NQF) announces the election of leadership ... NQF is a unique, multi-stakeholder, nonprofit ... healthcare by setting national priorities and goals for ... and publicly reporting on performance, and promoting the ...
    Cached Medicine Technology:Stereotaxis Reports Third Quarter Financial Results 2Stereotaxis Reports Third Quarter Financial Results 3Stereotaxis Reports Third Quarter Financial Results 4Stereotaxis Reports Third Quarter Financial Results 5Stereotaxis Reports Third Quarter Financial Results 6Stereotaxis Reports Third Quarter Financial Results 7National Quality Forum Members Elect New Council Leaders 2
    (Date:8/27/2014)... Aug. 26, 2014 (HealthDay News) -- Health care workers ... gear to keep them safe from being infected with ... study shows. While the study was conducted before ... spring, its findings are confirmed in statistics released Monday ... health agency reported that an "unprecedented" number of health ...
    (Date:8/27/2014)... and a new UCLA study has shown this is definitely ... decisions about how to treat their prostate cancer. , UCLA ... disease have a much more difficult time making treatment decisions, ... quality of their care and their long-term outcomes. , The ... can use the findings to target men less likely to ...
    (Date:8/27/2014)... CIC microGUNE, the Co-operative Research Centre into ... seeks to generate innovative solutions based on ... mobility industry and life sciences, among others. ... Tecnun are collaborating with CIC microGUNE on ... funded by the Etortek 2013-2014 programme of ...
    (Date:8/27/2014)... a week of tomatoes have an 18 per cent ... , With 35,000 new cases every year in the ... second most common cancer in men worldwide. , Rates ... is linked to a Westernised diet and lifestyle. , ... risk of prostate cancer, researchers at the Universities of ...
    (Date:8/27/2014)... news release is available in German . ... for medical agents to treat metastatic tumors. In case of ... that is often detected late, 95% of the patients die ... develops tumor therapeutic agents that might reduce this mortality rate. ... now received a total of EUR 5 million from investors. ...
    Breaking Medicine News(10 mins):Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 2Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 3Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Fighting prostate cancer with a tomato-rich diet 2Health News:Preclinical development of tumor therapeutic agent starts 2
    ... VP of Products and Marketing Will Address Growing Healthcare Trends ... Tools ... Michael Flanagan, VP of products,and marketing for Portico Systems, the ... Optimizing Provider,Network Management" at the Institute for International Research,s,conference in ...
    ... Barcelona, Spain: Recent political decisions have had serious ... at ECCO 14, the European Cancer Conference, today ... the Federation of European Cancer Societies (FECS) said ... take an active role in engaging with policymakers ...
    ... spontaneous quit attempts can be successful, PITTSBURGH, ... quit attempt may not be the path to ... for a quit attempt, a new national,survey conducted ... quitting may not require an advance plan.(1) In ...
    ... of Diabetic Neuropathy Market Will Be Driven by Launches, of ... ... Resources, WALTHAM, Mass., Sept. ... firms for pharmaceutical and,healthcare issues, finds that by 2016 Genentech/Roche,s Lucentis ...
    ... the Cure with its ... Emmy Award-winning journalist and TV personality Cristina ... Munchkin, Inc. -- maker of award-winning infant and ... again reminding women everywhere "Don,t Duck a ...
    ... to encourage an individual to get screened for ... according to researchers at Jefferson Medical College in ... interventions that guide recipients through the screening process ... primary care practices. , Ronald Myers, Ph.D., professor ...
    Cached Medicine News:Health News:Portico Systems to Share Provider Network Management Best Practices at Institute for International Research 2Health News:Political decisions harming cancer treatment in Europe 2Health News:Photos: New Survey Shows Many Successful Quit Smoking Attempts Made Without Advance Planning 2Health News:Photos: New Survey Shows Many Successful Quit Smoking Attempts Made Without Advance Planning 3Health News:Photos: New Survey Shows Many Successful Quit Smoking Attempts Made Without Advance Planning 4Health News:Genentech/Roche's Lucentis and Eli Lilly's Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets 2Health News:Cristina Saralegui Joins Celebrities Including Matthew McConaughey, Courteney Cox and Mariska Hargitay to Raise Money for Breast Cancer Research 2Health News:Jefferson researchers find personalized interventions key to improving colon cancer screening rates 2
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: